Agenus unit, MiNK surges after peer-reviewed data for lead drug

3 hours ago 1
  • Shares of MiNK Therapeutics (NASDAQ:INKT) climbed over 500% in the morning hours on Friday after the nano-cap cell therapy developer, which is a unit of Agenus (NASDAQ:AGEN), announced peer-reviewed data from a Phase 1 trial for

Recommended For You

More Trending News

Read Entire Article